Tiziana Life Sciences Ltd

詳細情報 Tiziana Life Sciences Ltd 企業名

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.

企業情報

企業コードTLSA

会社名Tiziana Life Sciences Ltd

上場日Nov 20, 2018

最高経営責任者「CEO」Mr. Ivor Elrifi

従業員数- -

証券種類Ordinary Share

決算期末Nov 20

本社所在地3rd Floor, 11-12 St. James's Square

都市LONDON

証券取引所NASDAQ Capital Market Consolidated

国United Kingdom

郵便番号SW1Y 4LB

電話番号442074952379

ウェブサイトhttps://www.tizianalifesciences.com/

企業コードTLSA

上場日Nov 20, 2018

最高経営責任者「CEO」Mr. Ivor Elrifi

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Willy Jules Simon

Non-Executive Independent Director

8.25K

--

Mr. John P. Brancaccio, CPA

Non-Executive Independent Director

--

Mr. Gabriele Marco Antonio Cerrone

Executive Chairman of the Board

--

Mr. Ivor Elrifi

Chief Executive Officer, Executive Director

--

Ms. Keeren Shah

Chief Financial Officer, Chief Operating Officer

--

Dr. William A. Clementi, Pharm.D.

Chief Development Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Willy Jules Simon

Non-Executive Independent Director

8.25K

--

Mr. John P. Brancaccio, CPA

Non-Executive Independent Director

--

Mr. Gabriele Marco Antonio Cerrone

Executive Chairman of the Board

--

Mr. Ivor Elrifi

Chief Executive Officer, Executive Director

--

Ms. Keeren Shah

Chief Financial Officer, Chief Operating Officer

--

Dr. William A. Clementi, Pharm.D.

Chief Development Officer

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Cerrone (Gabriele M)

37.71%

Chernett (Jorey)

5.34%

Dauntless Investment Group, LLC

3.07%

Citadel Advisors LLC

0.18%

HSBC Global Asset Management (UK) Limited

0.09%

他の

53.61%

株主統計

比率

Cerrone (Gabriele M)

37.71%

Chernett (Jorey)

5.34%

Dauntless Investment Group, LLC

3.07%

Citadel Advisors LLC

0.18%

HSBC Global Asset Management (UK) Limited

0.09%

他の

53.61%

種類

株主統計

比率

Individual Investor

43.06%

Investment Advisor

3.56%

Investment Advisor/Hedge Fund

0.28%

Hedge Fund

0.19%

Research Firm

0.11%

他の

52.80%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

68

51.10M

45.84%

+9.72M

2025Q1

69

45.10M

40.46%

+3.34M

2024Q4

64

40.33M

36.45%

-5.07M

2024Q3

58

41.30M

37.43%

-3.04M

2024Q2

51

40.27M

36.45%

-4.04M

2024Q1

48

40.16M

36.35%

-4.27M

2023Q4

52

45.25M

44.24%

+1.19M

2023Q3

58

45.24M

44.24%

+1.10M

2023Q2

54

45.32M

44.32%

+1.19M

2023Q1

53

45.06M

44.06%

+868.09K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Cerrone (Gabriele M)

42.04M

37.71%

+2.70M

+6.85%

Mar 31, 2025

Chernett (Jorey)

5.95M

5.34%

+5.95M

--

Jun 11, 2025

Dauntless Investment Group, LLC

1.74M

1.56%

+1.74M

--

Mar 31, 2025

HSBC Global Asset Management (UK) Limited

105.36K

0.09%

--

Mar 31, 2025

Zhang Financial LLC

96.26K

0.09%

+3.07K

+3.30%

Mar 31, 2025

Susquehanna International Group, LLP

57.33K

0.05%

+57.33K

--

Mar 31, 2025

HRT Financial LP

70.37K

0.06%

+70.37K

--

Mar 31, 2025

Kovitz Investment Group Partners, LLC

79.36K

0.07%

--

Mar 31, 2025

Geode Capital Management, L.L.C.

77.89K

0.07%

-167.84K

-68.30%

Mar 31, 2025

詳細を見る

1.780USD

Tiziana Life Sciences Ltd

1.780

概要

企業名

金融

分析